# A Safety and Efficacy Study of Eltrombopag in Subjects With AML

> **NCT01890746** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 148 (actual)

## Conditions studied

- Acute Leukaemia

## Interventions

- **DRUG:** Daunorubicin
- **DRUG:** Cytarabine
- **DRUG:** Eltrombopag
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01890746
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-05
- **Primary completion:** 2015-03-13
- **Final completion:** 2017-01-25
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2019-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01890746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01890746, "A Safety and Efficacy Study of Eltrombopag in Subjects With AML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01890746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*